{"id":2716,"date":"2019-10-07T20:24:44","date_gmt":"2019-10-07T18:24:44","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2716"},"modified":"2024-04-11T11:29:11","modified_gmt":"2024-04-11T09:29:11","slug":"pneumology","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/translational-medicine-area\/cardiovascular-respiratory-and-systemic-diseases-and-cellular-aging-program\/pneumology\/","title":{"rendered":"Pneumology"},"content":{"rendered":"\n

\n\t\tPneumology\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

The Pneumology research group is focused on looking for answers\u00a0 to respiratory clinical problems and therapeutical solutions on pneumologic diseases without effective treatments.<\/p>\n

 <\/p>\n

760<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"659px-xr_chest_-_pneumonia_with_abscess_and_caverns_-_d0\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tAlteracions inflamat\u00f2ries i del remodelat pulmonar en malalties cr\u00f2niques prevalents com la MPOC i minorit\u00e0ries com la Fibrosi Pulmonar, o agudes com el dany pulmonar associat a infecci\u00f3 respirat\u00f2ria,
\nLesi\u00f3 i alteraci\u00f3 de remodelat de via a\u00e8ria superior (estenosi traqueal i s\u00edndrome d’apnea del son \/ SAHS)
\nNoves aproximacions terap\u00e8utiques en insufici\u00e8ncia respirat\u00f2ria d’origen neuro-muscular\n\t\t\t\t\t
Selected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tSenage,T;Paul,A;Le Tourneau,T;Fellah Hebia,I; Vadori,M; Bashir,S; Galinanes,M et al, The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration<\/strong>, Nat. Med., 2022;28(2):283-294, doi:10.1038\/s41591-022-01682-w
\nCottin,V;Tomassetti,S;Valenzuela,C;Walsh,S;Antoniou,K;Bonella,F;Brown,KK et al, Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective., Am. J. Respir. Crit. Care Med., 2022;206(3):247-259, doi:10.1164\/rccm.202111-2607PP\n

Raghu,G;Remy Jardin,M; Richeldi,L; Thomson,CC; Inoue,Y; Johkoh,T; Kreuter,M et al, Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline<\/strong>, Am. J. Respir. Crit. Care Med., 2022;205(9):18-47, doi:10.1164\/rccm.202202-0399ST<\/p>\n

R\u00fcschoff,JH;Haberecker,M;Tsourti,Z;Nackaerts,K;de Perrot,M; Brcic,L; Nadal,E et al, Expression of phosphorylated ribosomal protein S6 in mesothelioma patients – correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project<\/strong>., Mod. Pathol., 2022;35(12):1888-1899, doi:10.1038\/s41379-022-01145-0<\/p>\n

Khor,YH;Bissell,B;Ghazipura,M;Herman,D;Hon,SM;Hossain,T;Kheir,F et al, Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis<\/strong>., Ann Am Thorac Soc, 2022;19(5):833-844, doi:10.1513\/AnnalsATS.202102-172OC<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

FIS22094. Integraci\u00f3n de las caracter\u00edsticas moleculares, gen\u00f3micas, morfol\u00f3gicas, y ambientales para mejorar el diagn\u00f3stico y tratamiento de precisi\u00f3n en Enfermedades Pulmonares Intersticiales Difusas fibrosantes (Precision-EPID)<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 3049970. 2023-2025. PI: Molina Molina, Maria.<\/p>\n

20FIS038. EFECTO DE LORATADINA EN LINFANGIOLEIOMIOMATOSIS<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 263603,37. 2020-2023. PI: Molina Molina, Maria.<\/p>\n

19FIS033. Caracterizaci\u00f3n de la fibrosis pulmonar telom\u00e9rica y su regulaci\u00f3n biol\u00f3gica<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 177870. 2019-2022. PI: Molina Molina, Maria.<\/p>\n

FIS21100. LOOKING FOR PREDICTIVE FACTORS AND PREVENTIVE MEASURES OF POSTCOVID19 INTERSTITIAL LUNG SEQUELAE<\/strong>. (POST-COVIL). Instituto de Salud Carlos III (ISCIII). Budget: 151250. 2022-2024. PI: Molina Molina, Maria.<\/p>\n

17ACL032. ESTUDIO OBSERVACIONAL EN VOLUNTARIOS SANOS Y PACIENTES CON EPOC PARA EVALUAR LA RELACI\u00d3N ENTRE LAS MEDICIONES CL\u00cdNICAS, RADIOL\u00d3GICAS Y DE BIOMARCADORES Y LA PROGRESI\u00d3N DEL ENFISEMA DURANTE UN PERIODO DE DOS A\u00d1OS<\/strong>. Boehringer Ingelheim Espa\u00f1a, S.A. Budget: 118222,88. 2017-2022. PI: Santos P\u00e9rez, Salud.<\/p>\n\t\t\t\t\tTechnology transfer<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tLicense: Process for manufacturing a costomizable medical device and deviced obtained by said process
\nPI: Dr. Antoni Rosell\nSpin-off: TRACTIVUS
\nPI: Dr. Antoni Rosell\n\t\t\t\t\"Maria-Molina-Molina2024\"\n

\n\t\tMolina Molina, Maria\n\t<\/h4>\n

\n\t\t\n\t\tmmolina@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Salud-Santos22\"\n

\n\t\tSantos P\u00e9rez, Salud\n\t<\/h4>\n

\n\t\t\n\t\tmsantosp@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\"Maria-Molina-Molina2024\"\n

\n\t\tMolina Molina, Maria\n\t<\/h4>\n

\n\t\t\n\t\tmmolina@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Guillermo-Rafael-Suarez-Cuartin\"\n

\n\t\tSu\u00e1rez Cuart\u00edn, Guillermo Rafael\n\t<\/h4>\n

\n\t\t\n\t\tgsuarez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Carmen-Monasterio-Ponsa\"\n

\n\t\tMonasterio Ponsa, Carmen\n\t<\/h4>\n

\n\t\t\n\t\tcmonasterio@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Salud-Santos22\"\n

\n\t\tSantos P\u00e9rez, Salud\n\t<\/h4>\n

\n\t\t\n\t\tmsantosp@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Mariana-Mu\u00f1oz-Esquerre\"\n

\n\t\tMu\u00f1oz Esquerre, Mariana Mercedes\n\t<\/h4>\n

\n\t\t\n\t\tmmunoz@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Marta-Diez-Ferrer\"\n

\n\t\tD\u00edez Ferrer, Marta\n\t<\/h4>\n\t\t\t\t\"Ana-Cordoba-Izquierdo\"\n

\n\t\tC\u00f3rdoba Izquierdo, Ana\n\t<\/h4>\n

\n\t\t\n\t\tacordoba@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Vanesa-Vicens-Zygmunt\"\n

\n\t\tVicens Zygmunt, Vanesa\n\t<\/h4>\n

\n\t\t\n\t\tvvicens@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Rosa-Maria-Lopez-Lisbona\"\n

\n\t\tLopez Lisbona, Rosa Maria\n\t<\/h4>\n

\n\t\t\n\t\trmlopez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"avatar\"\n

\n\t\tFarrero Mu\u00f1oz, Eva\n\t<\/h4>\n

\n\t\t\n\t\tefarrero@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tRELATED LINKS\n\t<\/h4>\n

\n\t\t\n\t\t@msaludsantos\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\t@EsquerreMunoz\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\t@Rosa96166501\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPrincipal investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPostdoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPredoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tManagement support\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t